Skye Bioscience, Inc. Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Detail Textuals)			1 Months Ended				3 Months Ended		9 Months Ended
Commitments and Contingencies (Detail Textuals)	Apr. 01, 2017 USD ($)	Feb. 05, 2016 USD ($)	Mar. 31, 2017 USD ($)	Nov. 30, 2015 USD ($)	Oct. 31, 2014 USD ($) ft²	Sep. 30, 2014 USD ($)	Sep. 30, 2017 USD ($)	Sep. 30, 2016 USD ($)	Sep. 30, 2017 USD ($)	Sep. 30, 2016 USD ($)
Operating Leased Assets [Line Items]
Rent expense				$ 7,559		$ 9,267	$ 54,555	$ 79,771	$ 168,863	$ 240,746
Monthly fee	$ 20,000		$ 10,000
Independent Contractor Agreements \| Contract manufacturing organization ("CMO")
Operating Leased Assets [Line Items]
Total expense incurred under agreement							60,000	30,000	150,000	90,000
Outstanding balance due to K2C							$ 150,000		$ 150,000
Lease agreement
Operating Leased Assets [Line Items]
Area of corporate office headquarters \| ft²					4,087
Rent expense					$ 5,373
Letter agreement ("Agreement") \| Contract manufacturing organization ("CMO")
Operating Leased Assets [Line Items]
Fees and expenses for the initial evaluation and development								$ 18,896		$ 225,244
Estimated analytical method development and qualification		$ 142,900
Letter agreement ("Agreement") \| Contract manufacturing organization ("CMO") \| Minimum
Operating Leased Assets [Line Items]
Fees and expenses for the initial evaluation and development		154,000
Letter agreement ("Agreement") \| Contract manufacturing organization ("CMO") \| Maximum
Operating Leased Assets [Line Items]
Fees and expenses for the initial evaluation and development		$ 183,000